🐯虎嗅•Stalecollected in 6h
BioMap IPO Rumors Hit HK
💡Baidu AI biotech BioMap IPO + 210B bio model launch
⚡ 30-Second TL;DR
What Changed
Founded 2020 by Li Yanhong; Xtrimo V1-V3 models up to 210B params.
Why It Matters
Boosts Baidu's AI bio push in hot HK IPO market; accelerates drug discovery AI.
What To Do Next
Test Xtrimo models on Hugging Face for protein design tasks.
Who should care:Researchers & Academics
Key Points
- •Founded 2020 by Li Yanhong; Xtrimo V1-V3 models up to 210B params.
- •Secret HK IPO filing amid AI pharma boom; port投 strategic partner.
- •Serves 800+ institutions; $2B potential orders; HK innovation hub.
🧠 Deep Insight
Web-grounded analysis with 8 cited sources.
🔑 Enhanced Key Takeaways
- •BioMap's core technology has evolved to the xTrimo V4 foundational model, which features 268 billion parameters, surpassing the previously reported 210B-parameter V3 version.
- •The company has undergone significant corporate restructuring, including a business registration change in September 2025 where Robin Li and Baidu-related entities exited the direct shareholder list to optimize equity for the IPO.
- •BioMap has secured strategic investment from the Hong Kong Investment Corporation (HKIC), which includes a commitment to prioritize Hong Kong as the primary listing destination for its IPO.
📊 Competitor Analysis▸ Show
| Competitor | Primary Focus | Key Differentiator |
|---|---|---|
| Insilico Medicine | Generative chemistry, aging | Clinical-stage assets (Phase II) |
| XtalPi | Physics-based simulation, robotics | Integrated wet-lab/dry-lab platform |
| Recursion | Phenomics, computer vision | Large-scale phenotypic screening |
| Schrödinger | Physics-based molecular modeling | Established pharma adoption/software |
| DeepMind (AlphaFold) | Protein structure prediction | Academic influence and foundational research |
🛠️ Technical Deep Dive
- xTrimo V4 Architecture: A 268-billion-parameter multimodal foundation model designed for cross-modal reasoning across DNA, RNA, proteins, cells, and biosystems.
- Data Modalities: Utilizes a proprietary dataset encompassing over 6 billion proteins and 100 billion protein-protein interactions.
- BioMap OS: A dry-wet closed-loop discovery system that integrates knowledge aggregation, predictive design, experimental control, and model training.
- Training Methodology: Employs a unified pre-training framework that enables simultaneous optimization for both protein understanding and de novo generation tasks.
- Inference Capabilities: Supports ultra-long sequence decoding (up to 128K) and achieves state-of-the-art performance across 300+ benchmarks in over 20 life science fields.
🔮 Future ImplicationsAI analysis grounded in cited sources
BioMap will achieve a successful HK IPO within 2026.
The company has already submitted confidential filings and is working with major investment banks (CICC, Morgan Stanley, UBS) to finalize the listing.
BioMap will enter clinical trials for an AI-designed drug by late 2027.
The company publicly announced an ambitious timeline to move its first AI-designed drug into clinical trials within two years of its late-2025 joint venture formation in Hong Kong.
⏳ Timeline
2020-08
BioMap founded by Robin Li and Liu Wei.
2021-07
Raised $100 million in Series A funding led by Legend Capital.
2023-10
Signed a potential $1 billion partnership with Sanofi for AI drug discovery modules.
2025-09
Completed corporate restructuring, removing Baidu entities from direct shareholding to prepare for IPO.
2026-03
Confidentially filed for an IPO on the Hong Kong Stock Exchange.
📎 Sources (8)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗